IBIO Quote, Financials, Valuation and Earnings

Bristol Myers Squibb Co. has a net margin of -5720% compared to iBio, Inc.'s net margin of 8.69%. iBio, Inc.'s return on equity of -80.97% beat Bristol Myers Squibb Co.'s return on equity of 39.9%.

iBio, Inc. has a consensus price target of $5.60, signalling upside risk potential of 97.88%. On the other hand Bristol Myers Squibb Co. has an analysts' consensus of $62.16 which suggests that it could fall by -0.27%. Given that iBio, Inc. has higher upside potential than Bristol Myers Squibb Co., analysts believe iBio, Inc. is more attractive than Bristol Myers Squibb Co..

iBio, Inc. has a beta of 1.180, which suggesting that the stock is 17.972% more volatile than S&P 500. In comparison Bristol Myers Squibb Co. has a beta of 0.265, suggesting its less volatile than the S&P 500 by 73.533%.

iBio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bristol Myers Squibb Co. offers a yield of 4% to investors and pays a quarterly dividend of $0.63 per share. iBio, Inc. pays -- of its earnings as a dividend. Bristol Myers Squibb Co. pays out 71.98% of its earnings as a dividend. Bristol Myers Squibb Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

iBio, Inc. quarterly revenues are --, which are smaller than Bristol Myers Squibb Co. quarterly revenues of $12.5B. iBio, Inc.'s net income of -$9M is lower than Bristol Myers Squibb Co.'s net income of $1.1B. Notably, iBio, Inc.'s price-to-earnings ratio is -- while Bristol Myers Squibb Co.'s PE ratio is 18.02x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iBio, Inc. is 420.73x versus 2.64x for Bristol Myers Squibb Co.. Usually stocks with elevated PS ratios are considered overvalued.

Recursion Pharmaceuticals, Inc. has a net margin of -5720% compared to iBio, Inc.'s net margin of -304.24%. iBio, Inc.'s return on equity of -80.97% beat Recursion Pharmaceuticals, Inc.'s return on equity of -63.64%.

iBio, Inc. has a consensus price target of $5.60, signalling upside risk potential of 97.88%. On the other hand Recursion Pharmaceuticals, Inc. has an analysts' consensus of $6.71 which suggests that it could grow by 84.46%. Given that iBio, Inc. has higher upside potential than Recursion Pharmaceuticals, Inc., analysts believe iBio, Inc. is more attractive than Recursion Pharmaceuticals, Inc..

iBio, Inc. has a beta of 1.180, which suggesting that the stock is 17.972% more volatile than S&P 500. In comparison Recursion Pharmaceuticals, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

iBio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Recursion Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iBio, Inc. pays -- of its earnings as a dividend. Recursion Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

iBio, Inc. quarterly revenues are --, which are smaller than Recursion Pharmaceuticals, Inc. quarterly revenues of $35.5M. iBio, Inc.'s net income of -$9M is higher than Recursion Pharmaceuticals, Inc.'s net income of -$108.1M. Notably, iBio, Inc.'s price-to-earnings ratio is -- while Recursion Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iBio, Inc. is 420.73x versus 21.86x for Recursion Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Senti Biosciences, Inc. has a net margin of -5720% compared to iBio, Inc.'s net margin of --. iBio, Inc.'s return on equity of -80.97% beat Senti Biosciences, Inc.'s return on equity of -173.17%.

iBio, Inc. has a consensus price target of $5.60, signalling upside risk potential of 97.88%. On the other hand Senti Biosciences, Inc. has an analysts' consensus of $11.50 which suggests that it could grow by 1107.48%. Given that Senti Biosciences, Inc. has higher upside potential than iBio, Inc., analysts believe Senti Biosciences, Inc. is more attractive than iBio, Inc..

iBio, Inc. has a beta of 1.180, which suggesting that the stock is 17.972% more volatile than S&P 500. In comparison Senti Biosciences, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

iBio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Senti Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iBio, Inc. pays -- of its earnings as a dividend. Senti Biosciences, Inc. pays out -- of its earnings as a dividend.

iBio, Inc. quarterly revenues are --, which are smaller than Senti Biosciences, Inc. quarterly revenues of --. iBio, Inc.'s net income of -$9M is higher than Senti Biosciences, Inc.'s net income of -$18.1M. Notably, iBio, Inc.'s price-to-earnings ratio is -- while Senti Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iBio, Inc. is 420.73x versus 3.27x for Senti Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vor Biopharma, Inc. has a net margin of -5720% compared to iBio, Inc.'s net margin of --. iBio, Inc.'s return on equity of -80.97% beat Vor Biopharma, Inc.'s return on equity of --.

iBio, Inc. has a consensus price target of $5.60, signalling upside risk potential of 97.88%. On the other hand Vor Biopharma, Inc. has an analysts' consensus of $44.60 which suggests that it could grow by 196.35%. Given that Vor Biopharma, Inc. has higher upside potential than iBio, Inc., analysts believe Vor Biopharma, Inc. is more attractive than iBio, Inc..

iBio, Inc. has a beta of 1.180, which suggesting that the stock is 17.972% more volatile than S&P 500. In comparison Vor Biopharma, Inc. has a beta of 1.989, suggesting its more volatile than the S&P 500 by 98.949%.

iBio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vor Biopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iBio, Inc. pays -- of its earnings as a dividend. Vor Biopharma, Inc. pays out -- of its earnings as a dividend.

iBio, Inc. quarterly revenues are --, which are smaller than Vor Biopharma, Inc. quarterly revenues of --. iBio, Inc.'s net income of -$9M is higher than Vor Biopharma, Inc.'s net income of -$812.7M. Notably, iBio, Inc.'s price-to-earnings ratio is -- while Vor Biopharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iBio, Inc. is 420.73x versus -- for Vor Biopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.